Sourcecontrol.bsky.social 🤜❤️‍🔥🤛 Challenger

#H5N1 prevention

opinion article ⤵️

Three things we can do now to reduce the risk of avian influenza spillovers

Kenneth B. Yeh kyeh@mriglobal.org,

William P. @wbahnfleth.bsky.social ,

Elaine Bradforda , and Matthew Scotch

July 30, 2025

doi.org/10.1073/pnas...

Opinion: Long COVID is solvable, but we need more clinical trials Some people may remain ill after COVID infection because the virus still lurks in their bodies. The looming question now is: Who will pay for drug development and trials?

PolyBio president Dr. Amy Proal outlines the direction that research must take to address long COVID in her new op-ed for @latimes.com: “The urgency of long COVID is a call to arms for government and private funders to help bring medications and protocols to the people who need them.”

Cell Volume 187, Issue 20, 3 October 2024, Pages 5500-5529 Review Mechanisms of long COVID and the path toward therapeutics Author links open overlay panelMichael J. Peluso 1 , Steven G. Deeks

Published October 2024
open access ✅️
👇
www.sciencedirect.com/science/arti...

Thanks ❤️‍🔥

18/ “We know what long COVID clinical trials to run - and we have a plan to do it," says Peluso. “Now we need everyone on board to collaborate and expand funding and industry support to make it happen. The health of millions is at stake.”

17/ "Advancing such tests represents a major opportunity for the biotech sector," says report first author Amy Proal PhD, who serves as President of the PolyBio Research Foundation.

16/ The report also highlights the urgent need to develop validated biomarkers capable of detecting persistent virus in accessible fluids like blood and saliva—an effort with immense potential to accelerate clinical trials, but one that remains underdeveloped.

15/ "We believe that combining therapies targeting both the virus and the immune system may be the best way forward, especially if dealing with persistent viral reservoirs in immune-protected tissues."

14/ "Our approach recognizes the importance of a multifactorial strategy," says report senior author Michael Peluso MD, an infectious disease researcher at the University of California, San Francisco (UCSF) School of Medicine.

13/ Combination Trials: Combining therapeutics - such as antivirals together with mAbs or immune system therapies - may be needed to most effectively target viral reservoirs.

12/ Viral RNA Targeting: Novel approaches such as CRISPR-based treatments could potentially deactivate persistent viral RNA, but further validation is needed.

11/ Immunotherapies: Restoring effective immune function with therapies like cytokine treatments or immune modulators could improve reservoir clearance.

10/ Antivirals: Short-term antiviral trials for long COVID have shown mixed results, but longer treatment durations - similar to those used in hepatitis C - may be necessary.

9/ Monoclonal Antibodies (mAbs): mAbs could neutralize the virus or boost the immune system’s ability to eliminate infected cells. Some mAbs are in early trials for long COVID, however many promising candidates remain untested.

8/ Drawing on what scientists have learned from other viral infections such as HIV, hepatitis C, and cancer clinical trials, the report outlines several promising approaches to treat long COVID patients with persistent SARS-CoV-2:

7/ "I have been sick for four years and I know the science is there," says long COVID patient Jon Douglas. "This report confirms that we have a plan for the trials that could finally help patients like me recover."

6/ The report, authored by 36 experts from 20 leading institutions worldwide, details key considerations for trial design, drug candidates, and viral persistence biomarker development.

5/ A new Viewpoint published in Lancet Infectious Diseases provides a roadmap for testing interventions aimed at clearing SARS-CoV-2 reservoirs.

4/ While early efforts are underway to treat these reservoirs, more well-designed clinical trials are desperately needed to treat and ultimately cure the millions suffering from long COVID.

3/ However, Long COVID is not a mystery. Research increasingly links the condition and its symptoms to persistent SARS-CoV-2 infection, with evidence showing that the virus can linger in reservoirs for months, or even years, in at least a subset of individuals.

2/ Medford, MA — Long COVID, a debilitating condition following SARS-CoV-2 infection, continues to disable tens of millions of people globally, yet no approved treatments exist.

Cutting-edge Recommendations Provide Treatment Path for Millions of Long COVID Patients - PolyBio Research Foundation In a new report, global experts outline key considerations to address persistent SARS-CoV-2; provide a roadmap to test critical new long...

1/ Cutting-edge Recommendations Provide Treatment Path for Millions of Long COVID Patients

In a new report, global experts outline key considerations to address persistent SARS-CoV-2; provide a
roadmap to test critical new long COVID therapies

polybio.org/cutting-edge...

Proud to have been a part of this
@polybiorf.bsky.social effort to describe the path forward for #LongCOVID trials targeting SARS-CoV-2 persistence. We need a robust biomarker development program and to launch more trials to rigorously test treatments that target these pathways now.

Nice op-ed from @polybiorf.bsky.social on the need for more Long COVID trials.

Mechanisms of long COVID and the path toward therapeutics Long COVID, a type of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC) defined by medically unexplained symp…

Citations from

Cell
Volume 187, Issue 20,
3. October 2024,
Pages 5500-5529

Review

Mechanisms of long COVID and the path toward therapeutics

Authors: ❤️‍🔥

Michael J. Peluso
[He is here, too👇] @michaelpelusomd.bsky.social

Steven G. Deeks

www.sciencedirect.com/science/arti...

Mechanisms of long COVID and the path toward therapeutics Long COVID, a type of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC) defined by medically unexplained symp…

Citations from

Cell
Volume 187, Issue 20,
3. October 2024,
Pages 5500-5529

Review

Mechanisms of long COVID and the path toward therapeutics

Authors: ❤️‍🔥

Michael J. Peluso
[He is here, too👇] @michaelpelusomd.bsky.social

Steven G. Deeks

www.sciencedirect.com/science/arti...

there is no cure for the tens of millions of people believed to be experiencing #LongCovid, and industry engagement in developing therapeutics has been limited.

the highest burden is among those with a history of mild-to-moderate illness, who comprise the vast majority of infected individuals

These outcomes represent a newly identified infection-associated chronic condition (IACC): long COVID.

Quelle des Screenshots

www.uni-muenster.de/Ejournals/in...